Johnson & Johnson shares jumped 1.2% in premarket trading on Tuesday after posting a strong first quarter. Both earnings and revenue beat analyst estimates, and the company slightly raised its full-year outlook. These results reinforce the stock’s position among 2026’s top large-cap performers, with shares up about 15% year-to-date, outperforming the nearly flat S&P 500.
Adjusted earnings for the first quarter were $2.70 per share, slightly above expectations. Sales reached $24.06 billion, about $450 million above analysts’ estimates and a 10% increase from last year. The Innovative Medicine segment led with over 11% sales growth, driven by the growing oncology portfolio. Meanwhile, the medical technology division grew by 7.7%, continuing its steady role as a secondary growth driver.
The company has raised its full-year outlook, now expecting sales of $100.3 to $101.3 billion and adjusted earnings of $11.45 to $11.65 per share. These modest increases reflect management’s measured confidence in demand, tempered by caution due to the uncertain economy.
Oncology is J&J’s top growth driver, anchored by three multiple myeloma drugs: Darzalex, Tecvayli, and Carvykti. Management targets $50 billion in cancer sales by 2030. Carvykti, a CAR-T cell therapy, achieved blockbuster status in 2025, boosting segment revenues. Although Darzalex faces patent expiry in the mid-2030s, J&J’s continued oncology innovation supports long-term growth.
Beyond oncology, J&J’s psychiatric drug portfolio is a growing focal point for analysts, especially with Caplyta, a recent acquisition through the purchase of Intra-Cellular Therapies and now approved as an add-on to antidepressants. While its blockbuster potential remains uncertain, Caplyta’s early gains broaden J&J’s earnings prospects in a market with little competition. Meanwhile, J&J’s valuation remains weighed down by talc litigation, with some 74,360 talc-related lawsuits still pending after a Texas bankruptcy court rejected the latest consolidation attempt. This ongoing legal uncertainty clouds an otherwise cleaner investment outlook, making litigation developments a key variable for traders assessing risk-adjusted returns. Despite this, J&J maintains its baby powder is safe and asbestos-free.
